Medication and orgasm: what changes, and how to tell

A lot of people notice that something changed after they started a new medication — orgasms take longer, feel muted, or stop arriving at all — and then quietly assume it's them. It usually isn't. For several very common drug classes, changes to orgasm are among the best-documented side effects there are. They're also among the least discussed, for reasons the research is unusually clear about.

This article covers what the evidence shows, why the numbers in a medication leaflet are probably too low, and how you'd actually tell a drug effect apart from an ordinary bad month. It is not medical advice, and nothing here is a reason to change how you take a prescription.

How common is it, really

The cleanest large study on antidepressants followed 1,022 outpatients across Spain and — importantly — enrolled only people whose sexual function was normal before they started treatment. Using a questionnaire that asked specifically about libido, orgasm, ejaculation, erectile function and overall satisfaction, 59.1% developed some form of sexual dysfunction (Montejo et al., 2001). Men reported it slightly more often than women (62.4% vs 56.9%), though women who had it rated it as more severe. Around 40% of affected patients said they tolerated it poorly.

A later meta-analysis limited itself to studies that asked directly, using proper questionnaires, in patients with no prior sexual difficulties. Depending on the specific drug, treatment-emergent sexual dysfunction affected between 25.8% and 80.3% of patients (Serretti & Chiesa, 2009). That's an enormous spread — and the spread is the point, which we'll come back to.

What actually changes

"Sexual side effect" is a vague phrase covering several distinct things, and they don't always arrive together:

• Delayed orgasm. The most characteristic effect of serotonergic antidepressants — orgasm still happens, but takes substantially longer.
• Muted or absent orgasm. Reduced intensity, or orgasm becoming unreliable or impossible.
• Reduced desire. Wanting sex less often, independent of whether the mechanics still work.
• Reduced arousal. Slower or weaker physical response — lubrication, erection — even when desire is intact.

These map onto separate phases of sexual response, and a drug can hit one while leaving another untouched. That matters practically: "my libido is fine but I can't finish" is a specific, recognisable pattern, not a contradiction. It's also why a single question like "any sexual side effects?" tends to miss things — the honest answer is often "some, but not the ones you're probably asking about."

Why you may not have been warned

This is the most useful finding in the whole area, and it explains the gap between what leaflets say and what people experience.

One study assessed the same 119 patients on an SSRI two different ways: with open-ended questions, and with direct, explicit questions about sexual function. Asked openly, 6% brought up a sexual problem. Asked directly, 41% reported one (Journal of Clinical Psychiatry, 2005). Same people, same medication, same week — a sevenfold difference produced entirely by how the question was posed.

Because pre-marketing trials have historically relied on volunteered reports, the incidence figures that end up in product literature are substantially lower than what shows up when anyone bothers to ask properly (Montejo et al., 2001; Serretti & Chiesa, 2009). If your experience doesn't match the "1 in 10 patients" line on the leaflet, the leaflet is the less reliable number.

The same study found something else worth knowing: sexual dysfunction did not correlate with how long people had been on the drug — which argues against the common reassurance that these effects reliably fade with time (Journal of Clinical Psychiatry, 2005). Some people do adapt. It isn't safe to assume you will.

It isn't only antidepressants

Hormonal contraception. Here the honest summary is that the average effect is small and the individual effect is not. A systematic review pooling 36 studies and 13,673 women found that among combined oral contraceptive users, 85% reported either no change or an increase in libido — and 15% reported a decrease (Pastor et al., 2013). A separate review reached the same shape of conclusion: mixed effects, a small proportion going each way, most women unaffected (Burrows et al., 2012). Pastor and colleagues also found no significant desire difference for pills containing 20–35 μg ethinylestradiol, with a decrease appearing only at the 15 μg dose.

Read that carefully, because it's easy to misread in both directions. "Most women are unaffected" is true. "Roughly one in six report their desire dropped" is also true. The population average tells you almost nothing about which group you're in — and that's precisely the situation where your own record is worth more than the study.

Blood-pressure medication. Effects here differ sharply by class. A 2024 evidence review concluded that beta-blockers remain the antihypertensive class most often associated with erectile dysfunction, though nebivolol appears to fare better; ACE inhibitors and angiotensin receptor blockers look neutral to positive, calcium-channel blockers broadly neutral, and older concerns about thiazides are not borne out by more recent evidence (Corona et al., 2024). The same review recommends assessing sexual function both at diagnosis and after starting a new drug — which is a clinical way of saying: get a baseline.

Alcohol and recreational drugs belong on this list too, alongside the everyday factors covered in what affects orgasm intensity.

Untangling the drug from the reason you're taking it

This is the genuinely hard part, and it deserves honesty rather than a clean answer. Depression and anxiety affect sexual function on their own. So does chronic illness. So does the stress of being unwell. When someone starts an antidepressant and their orgasms change, there are at least three candidate explanations tangled together: the drug, the condition, and everything else going on in their life.

Research handles this by enrolling only people whose sexual function was normal beforehand — which is exactly what the Montejo and Serretti studies did, and why their figures carry weight (Montejo et al., 2001; Serretti & Chiesa, 2009). You can borrow the same logic personally: the comparison that means something is you before versus you after, not you versus a population average.

Two things make that comparison much stronger. The first is having some record of the "before" — which is only possible if you started noticing before the change, or can reconstruct it honestly. The second is looking at the boundary rather than the overall average: what happened in the weeks either side of starting, and again either side of stopping or changing dose. A change that appears at both boundaries, in the same direction, is a far better signal than a vague sense that things have been worse lately.

The specific drug matters more than the class

One reason this is worth raising with a prescriber rather than just enduring: the differences between individual drugs are large, not marginal. In the Montejo study, incidence ranged from 72.7% on citalopram and 70.7% on paroxetine down to 24.4% on mirtazapine, 8% on nefazodone and 3.9% on moclobemide (Montejo et al., 2001). The meta-analysis found several agents — including bupropion, mirtazapine, moclobemide and agomelatine — showed no statistically significant difference from placebo on treatment-emergent sexual dysfunction, while sertraline, venlafaxine and citalopram sat at the high end (Serretti & Chiesa, 2009).

That's a real clinical conversation with real options — dose, timing, switching agents, adding something — and it's a conversation you can only have if the side effect gets mentioned. Which, per the 6%-versus-41% finding, it usually doesn't.

What a written record gives you that memory doesn't

Memory is unreliable in a specific, predictable way here: it flattens. A few months after a change you remember a general impression — "it's been harder lately" — but not whether the shift was sudden or gradual, whether it started before or after the new prescription, or whether frequency changed as much as intensity did. Those distinctions are exactly what a prescriber needs, and exactly what gets lost.

A record fixes that with fairly little effort. If you can say "in the two months before starting, I averaged around 7 out of 10 and reached orgasm almost every time; in the three months since, it's about 4, and roughly a third of the time it doesn't happen at all" — that's a completely different conversation from "I think it's been worse." It's also the kind of concrete detail that makes it easier to raise at all, which is half the problem. Our guide on talking about pleasure applies to clinicians as much as partners: specifics lower the temperature.

Frequency deserves its own mention, because it's the dimension people most often forget to track. If sex becomes reliably disappointing, most people gradually have less of it — so a drop in how often you're logging can be a downstream signal of a change in quality, and the two are worth looking at side by side.

This is one of the reasons Orgasmly exists, and why it can hold medication periods alongside your session history: you record when a medication started and stopped, and it compares intensity, frequency and completion rate on each side of those boundaries. Medication names stay private to your account — never in global statistics, never in a share link. You can see what that kind of view looks like before logging anything, and read more about how the privacy model works. If you're weighing up whether any of this is worth the effort, should you track your sexual wellbeing is the broader case.

The short version

Changes to orgasm after starting a medication are common, well-documented, and not a personal failing. The published incidence figures are probably understated, because most of them come from studies that waited for people to volunteer the information. The effect varies enormously between drugs and between people, which means the average tells you little and your own before-and-after tells you a lot. And the reason it's worth noticing carefully isn't self-diagnosis — it's that there are usually options, and they start with being able to describe what changed.

Sources

1. Montejo, A. L., Llorca, G., Izquierdo, J. A., & Rico-Villademoros, F. (2001). Incidence of Sexual Dysfunction Associated with Antidepressant Agents: A Prospective Multicenter Study of 1022 Outpatients. Journal of Clinical Psychiatry, 62(Suppl 3), 10–21. (Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction; enrolled only patients with previously normal sexual function.) https://pubmed.ncbi.nlm.nih.gov/11229449/
2. Serretti, A., & Chiesa, A. (2009). Treatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis. Journal of Clinical Psychopharmacology, 29(3), 259–266. (Restricted to studies using direct inquiry and specific questionnaires, in patients without pre-existing sexual dysfunction.) https://pubmed.ncbi.nlm.nih.gov/19440080/
3. Journal of Clinical Psychiatry (2005). Incidence of Sexual Side Effects in Refractory Depression During Treatment With Citalopram or Paroxetine. PubMed PMID: 15669895. (Compared open-ended questioning against direct questioning in the same 119 patients.) https://pubmed.ncbi.nlm.nih.gov/15669895/
4. Pastor, Z., Holla, K., & Chmel, R. (2013). The Influence of Combined Oral Contraceptives on Female Sexual Desire: A Systematic Review. European Journal of Contraception & Reproductive Health Care, 18(1), 27–43. (36 studies, 13,673 women.) https://doi.org/10.3109/13625187.2012.728643
5. Burrows, L. J., Basha, M., & Goldstein, A. T. (2012). The Effects of Hormonal Contraceptives on Female Sexuality: A Review. The Journal of Sexual Medicine, 9(9), 2213–2223. https://doi.org/10.1111/j.1743-6109.2012.02848.x
6. Corona, G., et al. (2024). Anti-hypertensive Medications and Erectile Dysfunction: Focus on β-blockers. Endocrine, 87(1), 11–26. https://doi.org/10.1007/s12020-024-04020-x